More recent trials in treatment-naive patients suggest that the combination of acalabrutinib, a second generation oral Btk inhibitor and obinutuzumab, a glycoengineered monoclonal antibody against CD20, is as efficacious and potentially better tolerated than conventional chemoimmunotherapy (3).